CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 8,641	$ 4,377	$ 26,612	$ 11,886
General and administrative	4,478	887	9,646	2,267
Total operating expenses	13,119	5,264	36,258	14,153
Loss from operations	(13,119)	(5,264)	(36,258)	(14,153)
Other income (expense):
Change in fair value of preferred stock tranche liability		(3,013)		(2,260)
Interest income	21	70	201	298
Other income (expense), net	9	(3)	5	(8)
Total other income (expense), net	30	(2,946)	206	(1,970)
Net loss and comprehensive loss	$ (13,089)	$ (8,210)	$ (36,052)	$ (16,123)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.85)	$ (13.21)	$ (3.01)	$ (27.48)
Weighted-average common shares outstanding, basic and diluted	15,334,241	621,581	11,991,870	586,728
Unrealized gain on marketable securities	$ 8		$ 8
Total other comprehensive income	8		8
Total comprehensive loss	$ (13,081)	$ (8,210)	$ (36,044)	$ (16,123)